MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
options
$29,468K
Proceeds from exercise of
warrants
$1,638K
Net cash provided by
financing activities
$29,520K
Canceled cashflow
$1,586K
Net change in cash,
cash equivalents and...
-$293,179K
Canceled cashflow
$29,520K
Maturities of marketable
securities
$122,063K
Share-based compensation
$59,425K
Fair value change -
derivative earnout and...
$18,783K
Changes in accounts
payable
$4,909K
Changes in accrued
expenses and other...
$2,448K
Depreciation and
amortization
$220K
Loss on disposal of
property, plant and...
-$12K
Transaction costs on issue of
ordinary shares and...
$1,586K
Net cash used in
investing activities
-$174,916K
Net cash used in
operating activities
-$147,783K
Canceled cashflow
$122,063K
Canceled cashflow
$85,797K
Foreign exchange
gains/(losses)
$13,055K
Purchases of marketable
securities
$296,733K
Loss for the year
-$203,819K
Purchase of property,
plant and equipment,...
$246K
Canceled cashflow
$13,055K
Changes in prepayments
(current and...
$13,280K
Foreign exchange
(gains)/losses
$13,055K
Changes in deferred
revenue
-$2,021K
Amortization of
premium/discount on...
-$1,405K
Interest income
$27,592K
Revenue
$22,503K
Segment adjusted loss
before tax
-$138,666K
Share-based compensation
expense
$59,425K
Change in fair value -
derivatives
$18,783K
Canceled cashflow
$50,095K
External r&d expense
$85,845K
Personnel expense
$40,788K
Manufacturing expense
$23,301K
Commercial programs
$19,296K
General and
administrative expense
$15,374K
Regulatory expense
$3,679K
Depreciation and
amortization
$478K
Back
Back
Cash Flow
source: myfinsight.com
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)